120家企业参与2025年药品目录谈判协商

Core Insights - The National Healthcare Security Administration (NHSA) has initiated negotiations for the 2025 National Basic Medical Insurance (BMI) drug list and the commercial insurance innovative drug list from October 30 to November 3, with participation from 120 domestic and foreign enterprises [1] - This year marks a significant change as the commercial insurance innovative drug list has been added to the directory adjustment process, running concurrently with the basic medical insurance directory work [1] - The new basic medical insurance drug list and the first version of the commercial insurance innovative drug list are expected to be released online and offline in Guangzhou on the first weekend of December, with implementation set for January 1, 2026 [1] Summary by Categories Negotiation and Participation - A total of 127 drugs outside the directory participated in the BMI drug list negotiations, while 24 drugs were involved in the price negotiations for the commercial insurance innovative drug list [1] Changes in Drug Listing Process - The inclusion of the commercial insurance innovative drug list in the directory adjustment process represents a new approach compared to previous years, indicating a shift towards integrating commercial insurance with basic medical insurance [1] Timeline for Implementation - The NHSA plans to complete the necessary technical, administrative, and legal procedures before the release of the new drug lists, which will be officially implemented starting January 1, 2026 [1]